PrenaTest STANDARD 2 (trisomy 21/13/18)

Prenatest Standard 2 (Trisomy 21/13/18)

We remind you that independent interpretation of the results is unacceptable, the information provided below is for reference purposes only.

Prenatest Standard 2 (Trisomy 21/13/18) is a non-invasive prenatal screening test that analyzes cell-free DNA (cfDNA) from the mother's blood to detect the presence of trisomies 21 (Down syndrome), 13 (Patau syndrome), and 18 (Edwards syndrome). These are chromosomal abnormalities that can lead to severe intellectual disabilities and physical deformities.

The Importance of Prenatal Screening

Prenatal screening tests are crucial for identifying potential genetic disorders or chromosomal abnormalities in the developing fetus. Early detection allows parents to make informed decisions and prepare for the birth of a child with special needs or consider other options, such as further diagnostic testing or, in some cases, termination of the pregnancy.

Table 1: Common Trisomies Screened by Prenatest Standard 2

The Prenatest Standard 2 screening test analyzes the cfDNA in the mother's blood, which contains fragments of the fetus's DNA. By detecting the presence of an extra copy of chromosomes 21, 13, or 18, the test can indicate an increased risk of the corresponding trisomy. However, it is important to note that this test is a screening tool, and diagnostic tests may be required to confirm the results.

Role of Prenatest Standard 2 (Trisomy 21/13/18)

The Prenatest Standard 2 (Trisomy 21/13/18) is a non-invasive prenatal screening test that analyzes cell-free DNA (cfDNA) from the mother's blood to assess the risk of the fetus having certain chromosomal abnormalities. Specifically, it screens for trisomies 21 (Down syndrome), 13 (Patau syndrome), and 18 (Edwards syndrome).

Indications for Ordering the Prenatest Standard 2 (Trisomy 21/13/18)

The Prenatest Standard 2 (Trisomy 21/13/18) is typically recommended for pregnant women who meet certain criteria, such as advanced maternal age, abnormal ultrasound findings, or a positive result from other screening tests. It can provide valuable information to help healthcare providers and expectant parents make informed decisions about further diagnostic testing and pregnancy management.

Preparation for the Procedure

The preparation for the Prenatest Standard 2 (Trisomy 21/13/18) analysis typically involves the following steps:

• No specific dietary restrictions are generally required. However, it is advisable to maintain a balanced diet and stay well-hydrated.
• Inform your healthcare provider about any medications or supplements you are taking, as some may potentially interfere with the test results.
• Discuss any recent illnesses, medical conditions, or treatments you have undergone, as these factors may influence the test outcomes.
• Follow any additional instructions provided by your healthcare provider or the laboratory regarding the preparation for the test.

Procedure for Sample Collection

The Prenatest Standard 2 (Trisomy 21/13/18) analysis typically involves a blood sample collection from a vein in the arm. The procedure is generally quick and straightforward, performed by trained healthcare professionals. After the blood draw, you may experience minor bruising or discomfort at the puncture site, which should resolve within a few days.

Turnaround Time

The turnaround time for the Prenatest Standard 2 (Trisomy 21/13/18) analysis can vary depending on the laboratory and their workflow. Typically, the results are available within 1-2 business days, excluding the day of sample collection.

It is important to note that various factors can potentially impact the turnaround time, such as:

• Laboratory workload and staffing levels
• Availability of necessary reagents and equipment
• Complexity of the analysis or the need for additional testing
• Transportation logistics for samples sent to external laboratories

Your healthcare provider or the laboratory staff can provide you with more specific information regarding the expected turnaround time for your particular case.

About the Prenatest Standard 2 (Trisomy 21/13/18)

The Prenatest Standard 2 (Trisomy 21/13/18) is a non-invasive prenatal screening test that analyzes cell-free DNA (cfDNA) in a pregnant woman's blood sample to evaluate the risk of the fetus having Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), or Trisomy 13 (Patau syndrome). This test is typically performed during the first or second trimester of pregnancy.

The analysis involves isolating and quantifying the cfDNA fragments from the maternal blood sample. By analyzing the relative amounts of specific chromosomal regions, the test can estimate the probability of the fetus having one of the three trisomies. However, it is essential to note that this test is a screening tool and does not provide a definitive diagnosis. Further diagnostic tests, such as amniocentesis or chorionic villus sampling, may be recommended if the screening results indicate an increased risk.

Sources:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686697/
https://pubmed.ncbi.nlm.nih.gov/32166736/
https://obgyn.onlinelibrary.wiley.com/doi/10.1002/uog.14664
https://www.stanfordchildrens.org/en/topic/default?id=trisomy-18-and-13-90-P02419

IMPORTANT!

It is crucial to remember that the information provided in this section is not intended for self-diagnosis or treatment. If you experience any discomfort or exacerbation of a condition, it is essential to consult a healthcare professional for appropriate diagnostic testing and treatment. Only a qualified specialist can make an accurate diagnosis and determine the appropriate treatment. To obtain the most accurate and consistent assessment of test results, it is recommended to have them performed at the same laboratory. This is because different laboratories may use different methods and units of measurement for similar tests.